Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus bevacizumab for chemotherapy-resistant MSI-like advanced colorectal cancer
NL-OMON49178Phase 2Completed
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in colorectal cancer (CRC), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Overall response rate. Started Mar 2018; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON49178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49178.